Transfection Reagents And Equipment Market Scope And Analysis

  • Report Code : TIPHE100001124
  • Category : Life Sciences
  • Status : Published
  • No. of Pages : 241
Buy Now

Transfection Reagents and Equipment Market Analysis, Size, and Growth (2023-2030)

Buy Now

Transfection Reagents and Equipment Market Report Transfection Reagents and Equipment Market Size and Share Transfection Reagents and Equipment Market Scope and Analysis

Transfection Reagents and Equipment Market Report Scope

Report Attribute Details
Market size in 2022 US$ 1.17 Billion
Market Size by 2030 US$ 2.15 Billion
Global CAGR (2022 - 2030) 7.8%
Historical Data 2020-2021
Forecast period 2023-2030
Segments Covered By Product
  • Reagents and Instruments
By Method
  • Viral Methods
  • Non Viral Methods
  • Hybrid Methods
By Application
  • Biomedical Research
  • Protein Production
  • Therapeutic Delivery
By End User
  • Academics & Research Institutes and Pharmaceutical & Biotechnology Companies
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Thermo Fisher Scientific Inc
  • Promega Corporation
  • Qiagen N V
  • Merck KGaA
  • Lonza Group
  • F Hoffmann La Roche Ltd
  • Bio Rad Laboratories Inc
  • Mirus Bio LLC
  • MaxCyte Inc

    • Industry Developments and Future Opportunities:

    One of the prominent initiative by key players operating in the Transfection Reagents and Equipment Market are listed below:

    1. In September 2023, Polyplus made the FectoVIR-LV transfection reagent for lentiviral vector (LV) synthesis available for pre-ordering. With this, the company also extended new design of experiment (DoE) services at no cost to optimize transfection conditions for better LV vector titers and quality in suspension systems. In suspension HEK-293 cell systems, FectoVIR-LV is a next-generation transfection that enhances LV production. The reagent has been engineered to reduce complexation volume and boost complex stability while maintaining its animal-free composition, making it suitable for large-scale production.

    Competitive Landscape and Key Companies:

    A few of the prominent players operating in the transfection reagents and equipment market are Thermo Fisher Scientific Inc., Promega Corporation, Qiagen N.V., Merck KGaA, Lonza Group, F.Hoffmann-La Roche Ltd, Bio-Rad Laboratories Inc., Mirus Bio LLC, MaxCyte Inc, and Polyplus-Transfection SA. These companies focus on new product launches and geographic expansions to meet the growing consumer demand worldwide and expand their product range with specialty portfolios. Their global presence allows them to serve a large base of customers, subsequently facilitating market expansion.